Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa™ (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy
INGELHEIM, Germany -- (BUSINESS WIRE) -- Boehringer Ingelheim has shared sub-analyses from the RE-DUAL PCI™ clinical trial at the AHA Scientific Sessions 2017 in Anaheim, California. RE-DUAL PCI™ i......
